B. Riley Brokers Boost Earnings Estimates for ARWR

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Equities research analysts at B. Riley upped their Q3 2025 earnings estimates for shares of Arrowhead Pharmaceuticals in a report issued on Tuesday, May 13th. B. Riley analyst M. Mamtani now forecasts that the biotechnology company will post earnings of ($1.24) per share for the quarter, up from their previous estimate of ($1.32). B. Riley currently has a “Buy” rating and a $38.00 target price on the stock. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($2.42) per share. B. Riley also issued estimates for Arrowhead Pharmaceuticals’ Q4 2025 earnings at $0.87 EPS, FY2025 earnings at $1.09 EPS, FY2026 earnings at ($3.23) EPS, FY2027 earnings at ($0.68) EPS, FY2028 earnings at ($2.10) EPS and FY2029 earnings at $0.57 EPS.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings results on Monday, May 12th. The biotechnology company reported $2.75 EPS for the quarter, beating the consensus estimate of ($0.06) by $2.81. The business had revenue of $542.71 million during the quarter, compared to analyst estimates of $116.27 million. During the same period last year, the firm posted ($1.02) earnings per share.

A number of other research firms have also issued reports on ARWR. Chardan Capital reissued a “buy” rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 13th. Royal Bank of Canada reissued an “outperform” rating and set a $42.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. Citigroup reduced their target price on shares of Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a “neutral” rating for the company in a research note on Tuesday, May 13th. StockNews.com raised shares of Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday. Finally, HC Wainwright reissued a “buy” rating and set a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, February 12th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.13.

Arrowhead Pharmaceuticals Trading Up 2.4%

NASDAQ ARWR opened at $15.71 on Friday. Arrowhead Pharmaceuticals has a one year low of $9.57 and a one year high of $30.41. The company has a 50-day simple moving average of $13.30 and a 200-day simple moving average of $17.79. The company has a debt-to-equity ratio of 7.27, a quick ratio of 6.09 and a current ratio of 6.09. The firm has a market capitalization of $2.17 billion, a PE ratio of -3.04 and a beta of 0.89.

Institutional Trading of Arrowhead Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. GAMMA Investing LLC lifted its stake in Arrowhead Pharmaceuticals by 297.6% during the first quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 1,628 shares during the last quarter. R Squared Ltd acquired a new stake in Arrowhead Pharmaceuticals during the fourth quarter valued at approximately $38,000. GF Fund Management CO. LTD. acquired a new stake in Arrowhead Pharmaceuticals during the fourth quarter valued at approximately $49,000. Van ECK Associates Corp lifted its stake in Arrowhead Pharmaceuticals by 72.3% during the fourth quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company’s stock valued at $56,000 after purchasing an additional 1,250 shares during the last quarter. Finally, CWM LLC lifted its stake in Arrowhead Pharmaceuticals by 134.3% during the first quarter. CWM LLC now owns 4,401 shares of the biotechnology company’s stock valued at $56,000 after purchasing an additional 2,523 shares during the last quarter. 62.61% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Arrowhead Pharmaceuticals

In related news, CEO Christopher Richard Anzalone sold 51,425 shares of the stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $15.07, for a total transaction of $774,974.75. Following the completion of the sale, the chief executive officer now directly owns 4,062,377 shares of the company’s stock, valued at $61,220,021.39. This represents a 1.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last three months, insiders sold 275,880 shares of company stock valued at $4,034,037. Company insiders own 4.30% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.